For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Enbrel, a mainstay biologic in the inflammation category, fell 4% overall, with net selling price down 22%. Amgen attributed ...

Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key ...

As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular ...

Will this pharma company become a new leader in the weight loss market?

Amgen Inc. experienced a cyber incident that involved the theft of patient information and proprietary data stored in cloud servers, it said in a filing Friday, the latest large healthcare company to ...

"We know they have the resources and the position to end their relationship with Marshall BioResources." ...

Amgen reached a $74 million settlement of a lawsuit accusing the biotechnology company of ​waiting too long to disclose that ...

The biotechnology company now expects full-year revenue between $38.2 billion and $39.4 billion, but said it was halting the ...

Amgen Q2 earnings preview: estimates, revenue outlook, Repatha/Tezspire growth, legacy declines & MariTide obesity pipeline ...

Three days ago, on August 4, Amgen ( AMGN) released another strong earnings report. Its revenue was $10.1 billion, up 16.6% ...